 Abbott Laboratories said it would sell a portion of its generics pharmaceuticals business to Mylan Inc in an allstock transaction valued at  billion that is the latest example of a healthcare deal driven in part to seek tax advantages Abbott will receive about a  stake or  million shares of a newly formed entity that will combine Mylans existing business and Abbotts generic pharmaceuticals business in developed markets not including the US The new entity will be organized in the Netherlands enabling the
  